| 1 |
Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-2509.
DOI
ScienceOn
|
| 2 |
Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
DOI
ScienceOn
|
| 3 |
Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-484.
DOI
ScienceOn
|
| 4 |
Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148.e1-5.
DOI
ScienceOn
|
| 5 |
Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-719.
|
| 6 |
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet 2009;374:989-997.
DOI
ScienceOn
|
| 7 |
Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-1738.
DOI
ScienceOn
|
| 8 |
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
DOI
ScienceOn
|
| 9 |
Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078.
DOI
ScienceOn
|
| 10 |
Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007;102:507-515.
DOI
ScienceOn
|
| 11 |
Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103:2465-2473.
DOI
ScienceOn
|
| 12 |
Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533-2549.
DOI
ScienceOn
|
| 13 |
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.
DOI
ScienceOn
|
| 14 |
Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718.
DOI
ScienceOn
|
| 15 |
Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944.
DOI
ScienceOn
|
| 16 |
Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a Cohort Study. Ann Intern Med 2010;152:337-345.
DOI
ScienceOn
|
| 17 |
Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes Study. Pharmacotherapy 2010;30:787-796.
DOI
ScienceOn
|
| 18 |
Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. Am Heart J 2009;157:369-374.
DOI
ScienceOn
|
| 19 |
Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a Cohort Study. Lancet 2009;373:309-317.
DOI
ScienceOn
|
| 20 |
Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a Nationwide Cohort Study. Ann Intern Med 2010;153:378-386.
DOI
ScienceOn
|
| 21 |
van Boxel OS, van Oijen MG, Hagenaars MP, Smout AJ, Siersema PD. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch Cohort Study. Am J Gastroenterol 2010;105:2430-2436, quiz 2437.
DOI
ScienceOn
|
| 22 |
Banerjee S, Weideman RA, Weideman MW, et al. Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention. Am J Cardiol 2011;107:871-878.
DOI
ScienceOn
|
| 23 |
Kim WH, Hong SP, Kim YH, et al. Effect of proton pump inhibitor and clopidogrel combination on the outcome of patients with ischemic heart disease. Korean J Med 2011;80:434-442.
|
| 24 |
Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med 2010;8:81.
DOI
ScienceOn
|
| 25 |
Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010;8:2624-2641, doi: 10.1111/j.1538-7836.2010.04049.X.
DOI
ScienceOn
|
| 26 |
U.S. Food and Drug Administration. FDA reminder to avoid concomitant use of plavix (clopidoregl) and omeprazle [Internet]. [cited 2010 Oct 27]. Available from: www.fda.gov/Drugs/DrugSafety/ucm231161.htm
|
| 27 |
Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010;105:34-41.
DOI
ScienceOn
|
| 28 |
Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-2436.
DOI
ScienceOn
|
| 29 |
Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-827.
DOI
ScienceOn
|
| 30 |
U.S. Food and Drug Administration. FDA announces new warning on plavix: avoid use with Prilosec/Prilosec OTC [Internet]. [cited 2009 Nov 18]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm
|
| 31 |
Beitelshees AL, McLeod HL. Clopidogrel pharmacogenetics: promising steps towards patient care? Arterioscler Thromb Vasc Biol 2006;26:1681-1683.
DOI
ScienceOn
|
| 32 |
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-362.
DOI
ScienceOn
|
| 33 |
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
DOI
ScienceOn
|
| 34 |
Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002;41:913-958.
DOI
ScienceOn
|
webmaster
